Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Rheumatoid arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time.

In 2017, the diagnosed prevalence of RA in the 8MM averaged 0.66% in adults 18 years of age and older and 2.7% in adults aged 60 and older. Early RA typically presents as a bilateral inflammatory joint condition, usually beginning in the smaller joints such as the fingers and toes and eventually progressing to the larger joints. Patients can experience flare-ups early in the disease onset, which are typically worse in the morning. Over time, pain and swelling may become constant, ultimately leading to deformity.

KEY QUESTIONS ANSWERED

With the increased entry of biosimilars into the RA marketplace, sales growth has begun to slacken and will likely continue to slow over the next 10 years.

  • How will biosimilar uptake differ cross the 8MM ?
  • What companies and drugs will be most affected by sales erosion from biosimilars?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are still many remaining unmet needs within the RA indication.

  • What are the main unmet needs in the RA market?
  • How can the pharmaceutical industry address these needs?
  • To what degree will the therapies under development fulfill these unmet needs?

Although biosimilars may slow the growth of the RA market, GlobalData expects that pipeline development of agents in the JAK inhibitor class as well as other novel oral agents , will powerfully shape the RA market going forward.

  • What are the main R&D trends in the RA market and which companies are leading the way?
  • Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?

Scope

Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global RA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global RA therapeutics market from 2017-2027.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Abbvie Inc

Pfizer Inc

Amgen Inc

Johnson & Johnson

Merck & Co Inc/Merck Sharp & Dohme

Bristol-Myers Squibb Co

F Hoffman-La Roche Ltd

Genentech Ltd ...

Abbvie Inc

Pfizer Inc

Amgen Inc

Johnson & Johnson

Merck & Co Inc/Merck Sharp & Dohme

Bristol-Myers Squibb Co

F Hoffman-La Roche Ltd

Genentech Ltd

Chugai Pharmaceutical Co Ltd

Biogen Inc

Eli Lilly and Co

UCB SA

Sanofi

Regeneron Pharmaceuticals Inc

Astellas Pharma Inc

Gilead Science Inc

Galapagos NV

R-Pharm

Taisho Pharmaceutical Holdings Co Ltd

Can-Fite BioPharma Ltd

AstraZeneca Plc

GlaxoSmithKline Plc

Samsung Bioepis Co Ltd

Celltrion Inc

Sandoz Inc

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar Erosion Will Temper Sales Growth in ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar Erosion Will Temper Sales Growth in the RA Market from 2017–2027

2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies

2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA patients

2.4 Pipeline JAK1 Inhibitors Are Best Equipped to Penetrate the Crowded RA Market

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.2.1 Preclinical RA

4.2.2 Early and Established RA

4.2.3 Therapeutic Mechanisms in RA

4.3 Symptoms and Severity Classifications

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Diagnosed Incident Cases of RA

5.4.4 Diagnosed Prevalent Cases of RA

5.4.5 Diagnosed Prevalent Cases of RA by Severity

5.4.6 Total Prevalent Cases of RA

5.5 Epidemiological Forecast for Rheumatoid Arthritis (2017–2027)

5.5.1 Diagnosed Incident Cases of RA

5.5.2 Age-Specific Diagnosed Incident Cases of RA

5.5.3 Sex-Specific Diagnosed Incident Cases of RA

5.5.4 Diagnosed Prevalent Cases of RA

5.5.5 Age-Specific Diagnosed Prevalent Cases of RA

5.5.6 Sex-Specific Diagnosed Prevalent Cases of RA

5.5.7 Diagnosed Prevalent Cases of RA by Severity

5.5.8 Total Prevalent Cases of RA

5.5.9 Age-Specific Total Prevalent Cases of RA

5.5.10 Sex-Specific Total Prevalent Cases of RA

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment

6.2 US

6.3 5EU

6.4 Japan

6.5 Australia

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the RA Market

7.2.1 Marketed Biosimilars

7.2.2 Pipeline Biosimilars

7.2.3 Pricing of Biosimilars Across the 8MM

7.2.4 Uptake of Biosimilars Across the 8MM

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.2.1 Improved Access to Rheumatologists

8.2.2 Diagnosis and Treatment of Early, Undifferentiated, and Preclinical RA

8.3 Cost-Effective Therapies

8.3.1 Biosimilars

8.3.2 Tofacitinib Generics

8.4 Personalized Treatment Strategies

8.5 Improved Guidance on Treating RA Patients in Remission

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 TNF Inhibitors

9.2.2 IL-6 Inhibitors

9.2.3 JAK Inhibitors

9.2.4 A3AR

9.3 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessments

10.3.1 AbbVie

10.3.2 Pfizer

10.3.3 Amgen

10.3.4 Johnson & Johnson

10.3.5 Bristol-Myers Squibb

10.3.6 Roche/Genentech

10.3.7 Eli Lilly

10.3.8 UCB

10.3.9 Sanofi

10.3.10 Astellas

10.3.11 Gilead

10.3.12 Galapagos

10.3.13 R-Pharm

10.3.14 Taisho

10.3.15 Can-Fite

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Australia

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic/Biosimilar Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs and Payers Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Epidemiology Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: RA: Key Metrics in the 8MM

Table 2: RA Disease Severity Classification

Table 3: Risk Factors and Comorbidities of RA

Table 4: 1987 ...

Table 1: RA: Key Metrics in the 8MM

Table 2: RA Disease Severity Classification

Table 3: Risk Factors and Comorbidities of RA

Table 4: 1987 ACR Diagnostic Criteria for RA

Table 5: Classification Criteria for Rheumatoid Arthritis – ACR 1987

Table 6: Classification Criteria for Rheumatoid Arthritis – ACR/EULAR 2010

Table 7: Treatment Guidelines for RA throughout the 8MM, 2018

Table 8: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials

Table 9: Country Profile – US

Table 10: Regional Profile – 5EU

Table 11: Country Profile – Japan

Table 12: Country Profile – Australia

Table 13: Leading Branded Treatments for RA, 2018

Table 14: Marketed Biosimilars for RA, 2018

Table 15: Pipeline Biosimilars for RA, 2018

Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2017

Table 17: AbbVie’s RA Portfolio Assessment, 2018

Table 18: Pfizer’s RA Portfolio Assessment, 2018

Table 19: Amgen’s RA Portfolio Assessment, 2018

Table 20: J&J’s RA Portfolio Assessment, 2018

Table 21: BMS’ RA Portfolio Assessment, 2018

Table 22: Roche/Genentech’s RA Portfolio Assessment, 2018

Table 23: Eli Lilly’s RA Portfolio Assessment, 2018

Table 24: UCB’s RA Portfolio Assessment, 2018

Table 25: Sanofi’s RA Portfolio Assessment, 2018

Table 26: Astellas’ RA Portfolio Assessment, 2018

Table 27: Gilead’s RA Portfolio Assessment, 2018

Table 28: Galapagos’ RA Portfolio Assessment, 2018

Table 29: R-Pharm’s RA Portfolio Assessment, 2018

Table 30: Taisho’s RA Portfolio Assessment, 2018

Table 31: Can-Fite’s RA Portfolio Assessment, 2018

Table 32: RA Market – Global Drivers and Barriers, 2017–2027

Table 33: Key Events Impacting Sales for RA in the US, 2017–2027

Table 34: RA Market – Drivers and Barriers in the US, 2017–2027

Table 35: Key Events Impacting Sales for RA in the 5EU, 2017–2027

Table 36: RA Market – Drivers and Barriers in the 5EU, 2017–2027

Table 37: Key Events Impacting Sales for RA in Japan, 2017–2027

Table 38: RA Market – Global Drivers and Barriers in Japan, 2017–2027

Table 39: Key Events Impacting Sales for RA in Australia, 2017–2027

Table 40: RA Market – Global Drivers and Barriers in Australia, 2017–2027

Table 41: Key Historical and Projected Launch Dates for RA

Table 42: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA

Table 43: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for RA in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in RA During the ...

Figure 1: Global Sales Forecast by Country for RA in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period

Figure 4: Overview of RA Pathogenesis and Pathophysiology

Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs

Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2017

Figure 7: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Men, Ages ≥18 Years, 2007 to 2027

Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Women, Ages ≥18 Years, 2007 to 2027

Figure 9: 8MM, Age-Standardized Total Prevalence of RA (%), Men, Ages ≥18 Years, 2007 to 2027

Figure 10: 8MM, Age-Standardized Total Prevalence of RA (%), Women, Ages ≥18 Years, 2007 to 2027

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA

Figure 12: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA

Figure 13: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA

Figure 14: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N, 2017

Figure 17: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N, 2017

Figure 20: 8MM, Diagnosed Prevalent Cases of RA By Severity, Both Sexes, Ages ≥18 Years, N, 2017

Figure 21: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 22: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017

Figure 23: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2017

Figure 24: General Treatment Algorithm for RA Patients

Figure 25: Physicians Reporting Prescription of Biosimilars to at Least 25%, 50%, or 75% of Their RA Patients Throughout the 8MM, 2018

Figure 26: Physicians Reporting Prescription of Biosimilars to at Least 50% of Their RA Patients Throughout the 5EU, 2018

Figure 27: Prescription of Etanercept, Infliximab, and Rituximab Biosimilars in Comparison to Reference Biologics Among 5EU Physicians, 2017

Figure 28: Unmet Needs and Opportunities in RA, 2018

Figure 29: Overview of the Development Pipeline in RA

Figure 30: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for RA in the 8MM During the Forecast Period

Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period, 2017–2027

Figure 32: Analysis of the Company Portfolio Gap in RA During the Forecast Period

Figure 33: Global (8MM) Sales Forecast by Country for RA in 2017 and 2027

Figure 34: Global (8MM) Sales Forecast for RA, by Class, in 2017 and 2027

Figure 35: Sales Forecast by Class for RA in the US in 2017 and 2027

Figure 36: Sales Forecast by Class for RA in the 5EU in 2017 and 2027

Figure 37: Sales Forecast by Class for RA in Japan in 2017 and 2027

Figure 38: Sales Forecast by Class for RA in Australia in 2017 and 2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports